Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 183 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Acute Respiratory Syndrome (SARS) Pneumonia Clear all
Completed Phase 3 Interventional Results available

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780268
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
42
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jul 23, 2026, 6:47 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780424
View directory record Official record
Conditions
COVID-19
Interventions
BRII-196, BRII-198, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
76
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910
View directory record Official record
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 6:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

NCT07093580
View directory record Official record
Conditions
Healthy Participants
Interventions
S-892216-LAI, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 23, 2026, 6:47 AM EDT
Completed No phase listed Observational

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

NCT04367740
View directory record Official record
Conditions
Asymptomatic Condition, Infection Viral, Coronavirus Infections, Severe Acute Respiratory Syndrome Coronavirus 2, Coronaviridae Infections, RNA Virus Infections, Virus Diseases, Communicable Disease
Interventions
To assess for development of IgG antibodies against SARS-CoV2
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
6,313 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Jul 23, 2026, 6:47 AM EDT
Terminated Not applicable Interventional Results available

Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19)

NCT04610489
View directory record Official record
Conditions
Covid-19
Interventions
Quidel Sofia SARS Antigen FIA
Diagnostic Test
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

NCT04412668
View directory record Official record
Conditions
SARS-CoV-2 (COVID-19) Severe Pneumonia
Interventions
Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 23, 2026, 6:47 AM EDT
Terminated Phase 2 Interventional Results available

COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes

NCT04537299
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 23, 2026, 6:47 AM EDT
Not listed Phase 4 Interventional

IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation

NCT04616001
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
IVIG
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Jul 23, 2026, 6:47 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

NCT04547140
View directory record Official record
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 23, 2026, 6:47 AM EDT
Recruiting Phase 2 Interventional

Imaging Immune Activation in COVID-19

NCT04815096
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Drug
Lead sponsor
CellSight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 6:47 AM EDT
Terminated Phase 2 Interventional Results available

Study of Varespladib in Patients Hospitalized With Severe COVID-19

NCT04969991
View directory record Official record
Conditions
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Varespladib, Placebo
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Ventura, California • Miami, Florida • Munster, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Strain Change Study for SARS-CoV-2 rS Vaccines

NCT06409663
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Interventions
NVX-CoV2705 Vaccine
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

NCT04519437
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
REGN10933+REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 23, 2026, 6:47 AM EDT
Terminated Phase 2 Interventional Results available

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

NCT04409873
View directory record Official record
Conditions
COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease, Coronavirus Infections, Pharyngeal Diseases
Interventions
Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash, Distilled water, Listerine Zero Mouthwash Product
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

NCT04510194
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Metformin, Placebo, Fluvoxamine, Ivermectin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 85 Years
Enrollment
1,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Sylmar, California • Aurora, Colorado • Golden, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

NCT04960202
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332, Ritonavir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
73
States / cities
Pelham, Alabama • Mesa, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial

NCT04847349
View directory record Official record
Conditions
Covid19
Interventions
OL-1, standard dose, OL-1, high dose, Placebo
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

NCT04419025
View directory record Official record
Conditions
COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions
N-acetylcysteine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

NCT05629962
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
Interventions
Bemnifosbuvir (BEM), Placebo
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Kingman, Arizona • Prescott, Arizona • Surprise, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 23, 2026, 6:47 AM EDT
Withdrawn Phase 2 Interventional

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

NCT04725110
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions
Instilled T3, Placebo Therapy
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 23, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

NCT05263921
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jul 23, 2026, 6:47 AM EDT